相关实验视频
Updated: Aug 12, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.9K
基于酸盐的药物载体系统以向炎性肠病:一篇评论
Dinakar Swastha1, Nambolan Varsha1, Suresh Aravind1
1Biopharmaceuticals Lab, Department of Biotechnology, School of Bioengineering, SRMInstitute of Science and Technology, Kattankulathur, Chennai, 603203, Tamilnadu, India.
International journal of biological macromolecules
|June 19, 2023
概括
来自海洋的酸盐 (AG) 在炎症性肠病 (IBD) 治疗中表现有前途. 基于AG的药物输送系统为治疗IBD症状提供了有针对性的治疗方法,并提高了治疗IBD症状的有效性.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 是一个日益严重的全球健康问题,其病理生理学尚不清楚.
- 目前的IBD治疗方法侧重于症状管理,而不是解决根本原因.
研究的目的:
- 审查IBD的病原和当前治疗方法.
- 探索基于酸盐 (AG) 的药物输送系统,以缓解IBD.
- 讨论生物制药中AG的未来挑战和机遇.
主要方法:
- 文献综述侧重于IBD的发病,治疗和基于酸盐的药物输送系统.
- 对阿尔金酸盐的特性 (生物相容性,pH敏感性,交叉连接) 的分析,用于药物输送应用.
- 基于纳米技术的系统和水凝的检查,利用酸盐进行有针对性的输送.
主要成果:
- 酸 (AG) 是一种生物相容,pH敏感和可交叉链接的海洋多糖.
- 基于AG的系统,包括水凝和纳米载体,可实现IBD的持续和有针对性的药物释放.
- 这些系统可以提供各种治疗剂,如药物,siRNA,介质蛋白和干细胞.
结论:
- 酸盐 (AG) 为开发IBD的先进药物输送系统提供了一个多功能,具有成本效益和无毒的平台.
- 基于AG的载体提高治疗效率,降低剂量,并促进部位导向的分娩和组织再生.
- 对AG的进一步研究具有改善IBD管理中的生物制药应用的巨大潜力.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...